Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc. (CXM) Commercialization Status For Excellagen 0 comments
    Feb 5, 2013 2:54 PM | about stocks: CXM

    Cardium Therapeutics has a capital-efficient, asset-based business strategy focused on building a diversified portfolio of new and innovative bio-medical product opportunities and businesses, leveraging research and development investments by big pharma, venture, and institutional investors. A key component to that strategy is the company's Excellagen advanced wound care management platform, which has already received FDA 510(k) clearance for U.S. marketing and sales.

    Excellagen is a syringe-based flowable topical gel that promotes the activation of the healing process for the treatment of dermal wounds. It is designed to accelerate granulation tissue growth in non-healing wounds and activates platelets, triggering the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biologic mediator of wound healing.

    Its initial focus is for diabetic foot ulcers, a significant problem in the U.S. with its growing population of diabetic patients. The Excellagen plan is consistent with the company's strategy of supporting initial market introduction, seeding the market, and then monetizing through strategic partnerships and distribution deals, both domestically and internationally.

    Principal commercialization factors:

    • Excellagen is the best-in-class acellular biological modulator designed to accelerate the growth of granulation tissue for wound healing.
    • Excellagen has FDA clearance for the treatment of a broad array of dermal wounds.
    • Excellagen is competitively positioned, offering an aseptically manufactured, pharmaceutically-formulated collagen in a flowable syringe-based format that is easy to use.
    • Excellagen has multiple clinical studies backing up its unique effectiveness.
    • Selected as 2012 Top 10 Innovation in Podiatry by Podiatry Today magazine.
    • Excellagen outsourced supply chain is fully operational, including U.S. cold chain distributor: Smith Medical Partners.

    International CE mark registration for Excellagen is targeted for 1Q/2013

    For additional information, visit www.CardiumTHX.com

    Sign up for "The Mission Report" at www.MissionIR.com

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.